Brain-derived neurotrophic factor gene polymorphisms: influence on treatment response phenotypes of major depressive disorder
The DOI matches its Crossref record, with a small difference in title or year; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Brain-derived neurotrophic factor (BDNF), a member of the nerve growth factor family of neurotrophins, has pivotal roles in neuronal survival, proliferation, and synaptic plasticity in the brain. Both clinical and pharmacological studies have implicated the common single nucleotide polymorphism (SNP) at position 196, Val66Met in the pathophysiology of major depressive disorder (MDD), and antidepressant response. However, inconsistent results were found between Val66Met (rs6265) polymorphism and treatment response phenotypes in genetic association studies. The functional Val66Met polymorphism and seven other tagging SNP markers selected to capture the major allelic variations across BDNF locus were analyzed in depressed patients, treated with antidepressants, and 76 control patients. Two hundred and six patients with Diagnostic and Statistical Manual of Mental Disorders-IV MDD were recruited for this study and genotyped for eight BDNF tagging SNPs (rs11030096, rs925946, rs10501087,rs6265, rs12273363, rs908867, rs1491850, and rs1491851)to investigate the functional impact of genotypes/haplotypes in the susceptibility of depression and on treatment response. None of the eight SNPs, including the rs6265, were significantly associated with MDD after permutation correction. However, we found an association for rs10501087, rs6265 with nonresponse to antidepressant treatment (corrected permutation P:0.03599; 0.0399 and power: 0.1420; 0.1492, respectively).Analysis of each two-marker, three-marker, and four-marker sliding window haplotypes showed significance in haplotype combinations. Especially rs10501087 (C), rs6265 (A), and rs149,1850 (C) together or with the other SNP haplotypes showed a similar pattern in all treatment response phenotypes. Despite the limited power of analysis, our results suggest that these three SNPs may play a role in antidepressant treatment response phenotypes in MDD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In patients with major depressive disorder, the BDNF val66met SNP, as well as two other BDNF SNPs, were linked to a reduced response to antidepressant treatment suggesting that these SNPs may impact treatment responses to antidepressants (Kocabas et al., 2011).”
From BDNF - a key transducer of antidepressant effects (2016) · cites this paper as Kocabas et al., 2011
Citations
Cites
Egan, M. F., Kojima, M., Callicott, J. H., Goldberg, T. E., Kolachana, B. S., Bertolino, A., Zaitsev, E., Gold, B., Goldman, D., Dean, M., et al. (2003) · Cell · doi:10.1016/s0092-8674(03)00035-7 · Cited by 3,888 · cited 7×
“Sequence variations in the BDNF gene, which may lead to variations in gene expression or protein metabolism have been advanced as possible causes of selective neuronal vulnerability (Egan et al., 2003).”
BackgroundInfluentialThe molecular neurobiology of depression
Krishnan, V., & Nestler, E. J. (2008) · Nature · doi:10.1038/nature07455 · Cited by 2,889 · cited 12×
“these effects are both region-specific and antidepressantspecific (Krishnan and Nestler, 2008).”
BackgroundInfluentialEvidence-based health policy—lessons from the Global Burden of Disease Study
Murray, C. J. L., & Lopez, A. D. (1996) · Science · doi:10.1126/science.274.5288.740 · Cited by 2,178
Sen, S., Duman, R., & Sanacora, G. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.05.005 · Cited by 1,232
Hariri, A. R., Goldberg, T. E., Mattay, V. S., Kolachana, B. S., Callicott, J. H., Egan, M. F., & Weinberger, D. R. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-17-06690.2003 · Cited by 1,045 · cited 1×
“Recent human studies have indicated that Val66Met polymorphism has an impact on episodic memory, hippocampal morphology, and memory-related hippocampal activity (Egan et al., 2003; Hariri et al., 2003; Hashimoto, 2007).”
BackgroundBrunoni, A. R., Lopes, M., & Fregni, F. (2008) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145708009309 · Cited by 972
SNP Genotyping Using the Sequenom MassARRAY iPLEX Platform
Gabriel, S., Ziaugra, L., & Tabbaa, D. (2009) · Current Protocols in Human Genetics · doi:10.1002/0471142905.hg0212s60 · Cited by 969
Pruunsild, P., Kazantseva, A., Aid, T., Palm, K., & Timmusk, T. (2007) · Genomics · doi:10.1016/j.ygeno.2007.05.004 · Cited by 699 · cited 2×
“have been identified in all examined brain regions (Pruunsild et al., 2007).”
BackgroundWang, J.-W., David, D. J., Monckton, J. E., Battaglia, F., & Hen, R. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.3632-07.2008 · Cited by 550
Souery, D., Oswald, P., Massat, I., Bailer, U., Bollen, J., Demyttenaere, K., Kasper, S., Lecrubier, Y., Montgomery, S., Serretti, A., et al. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0713 · Cited by 521 · cited 1×
“Detailed information on the diagnosis, recruiting method, and treatment response phenotypes of patients have been published by our group (Souery et al., 2007).”
MethodSelf-citation
Cited by
BDNF - a key transducer of antidepressant effects
Björkholm, C., & Monteggia, L. M. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.10.034 · Cited by 958
“In patients with major depressive disorder, the BDNF val66met SNP, as well as two other BDNF SNPs, were linked to a reduced response to antidepressant treatment suggesting that these SNPs may impact treatment responses to antidepressants (Kocabas et al., 2011).”
BackgroundPharmacogenetics in major depression: A comprehensive meta-analysis
Niitsu, T., Fabbri, C., Bentini, F., & Serretti, A. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.05.011 · Cited by 190
“The excluded studies focused on the association between rs6265 and AD efficacy reported positive associations (Kocabas et al., 2011; Mandelli et al., 2010; Xu AC C EP TE D M AN U SC R IP T et al., 2012a; Zou et al., 2010a), or no association (Domschke et al., 2010; Huuhka et al., 2007).”
Brain-derived neurotrophic factor and inflammation in depression: Pathogenic partners in crime?
Porter, G. A., & O’Connor, J. C. (2022) · World Journal of Psychiatry · doi:10.5498/wjp.v12.i1.77 · Cited by 178
Bartova, L., Dold, M., Kautzky, A., Fabbri, C., Spies, M., Serretti, A., Souery, D., Mendlewicz, J., Zohar, J., Montgomery, S., et al. (2019) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2019.1635270 · Cited by 152
“Several SNPs in the BDNF gene, including the functional Val66Met polymorphisms rs6265, rs11030104 and rs11030101, may affect the risk of treatment resistance but not suicidality (Kocabas et al. 2011; Schosser et al. 2012b, 2017; Fabbri et al. 2014, 2017a).”
BackgroundSelf-citationSchosser, A., Serretti, A., Souery, D., Mendlewicz, J., Zohar, J., Montgomery, S., & Kasper, S. F. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.02.006 · Cited by 145
Self-citationADHD: Reviewing the Causes and Evaluating Solutions
Núñez-Jaramillo, L., Herrera-Solís, A., & Herrera-Morales, W. V. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11030166 · Cited by 143
“For example, some articles report an association of this SNP with major depressive disorder [69,73], while other studies fail to find this association [74,75].”
BackgroundKautzky, A., Baldinger, P., Souery, D., Montgomery, S., Mendlewicz, J., Zohar, J., Serretti, A., Lanzenberger, R. R., & Kasper, S. F. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.01.001 · Cited by 100
“…TRD in a pan-european sample for over a decade, demonstrated the importance of genes as COMT, CREB, PPP3CC, ST8SIA2 and BDNF, involved in transcription, catecholamine inactivation and neuroplasticity (Fabbri et al., 2014; Kocabas et al., 2010; Kocabas et al., 2011; Schosser et al., 2012b).”
BackgroundSelf-citationPilar-Cuéllar, F., Vidal, R., Díaz, A., Castro, E., dos Anjos, S., Pascual-Brazo, J., Linge, R., Vargas, V., Blanco, H., Martínez-Villayandre, B., et al. (2013) · Neural Plasticity · doi:10.1155/2013/537265 · Cited by 90
“This polymorphism is also associated to nonresponders after antidepressant treatment [176].”
Mechanisms underlying the antidepressant response and treatment resistance
Levinstein, M. R., & Samuels, B. A. (2014) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2014.00208 · Cited by 102
“By contrast, it was also reported that the Val66Met mutation resulted in resistance to antidepressant treatment (Kocabas et al., 2011).”
BackgroundPharmacogenetics of major depressive disorder: top genes and pathways toward clinical applications
Fabbri, C., & Serretti, A. (2015) · Current Psychiatry Reports · doi:10.1007/s11920-015-0594-9 · Cited by 84
Pharmacogenetics of antidepressant drugs: An update after almost 20 years of research
Fabbri, C., Di Girolamo, G., & Serretti, A. (2013) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32184 · Cited by 82
“…studies mainly suggested a positive molecular heterosis effect [Tsai et al., 2003; Yoshida et al., 2007; Zou et al., 2010], together with a more favorable outcome in Met allele carriers [Choi et al., 2006; Alexopoulos et al., 2010; Taylor et al., 2010b; Kocabas et al., 2011a] (Table I).”
BackgroundInfluentialMultisensory Stimulation in Stroke Rehabilitation
Johansson, B. B. (2012) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2012.00060 · Cited by 82
Mikoteit, T., Beck, J., Eckert, A., Hemmeter, U., Brand, S., Bischof, R., Holsboer‐Trachsler, E., & Delini‐Stula, A. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3475-8 · Cited by 72
“Additionally, we could not take into account status of functionally relevant BDNF-gene-polymorphisms like the val66met polymorphism: meta-analyses show that heterozygotes are more likely to respond to antidepressant treatment than homozygotes (Kocabas et al. 2011; Zou et al. 2010).”
BackgroundAre there meaningful biomarkers of treatment response for depression?
Breitenstein, B., Scheuer, S., & Holsboer, F. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.02.002 · Cited by 74
“…Paroxetine, sertraline 66 val/met (rs6265) No association Taylor et al. (2011) [142] 210 Caucasian Various ADs 66 val/met (rs6265) Met allele Kocabas et al. (2011) [154] 206 Caucasian Various ADs 8 tagging SNPs within BDNF (including 66 val/met) rs10501087 C allele, rs6265 A allele,…”
Novel biomarkers in major depression
Schneider, B., & Prvulovic, D. (2013) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e32835a5947 · Cited by 65
Lullau, A. P. M., Haga, E. M. W., Ronold, E. H., & Dwyer, G. E. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1223145 · Cited by 67
“Further supporting the importance of BDNF in antidepressant response, the Val66Met as well as two other BDNF SNPs have been associated with an attenuated response to conventional antidepressant treatment in a human clinical trial (Kocabas et al., 2011).”
BackgroundThe Neurotrophic Hypothesis of Depression Revisited: New Insights and Therapeutic Implications
Jaggar, M., Fanibunda, S. E., Ghosh, S., Duman, R. S., & Vaidya, V. A. (2019) · Neurobiology of Depression · doi:10.1016/b978-0-12-813333-0.00006-8 · Cited by 54
Honea, R. A., Cruchaga, C., Perea, R. D., Saykin, A. J., Burns, J. M., Weinberger, D. R., Goate, A. M., & (ADNI), F. T. A. D. N. I. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076001 · Cited by 58
“Similarly, other tagging SNPs implicated in risk for depression as well as anti-depressant treatment response, such as rs1491850, rs10501087, rs908867 [36,37], were both related to increased hippocampal atrophy in our sample of elderly individuals, highlighting the complexity of this gene and its involvement in brain…”
Colle, R., Deflesselle, E., Martin, S., David, D. J., Hardy, P., Taranu, A., Falissard, B., Verstuyft, C., & Corruble, E. (2015) · Pharmacogenomics · doi:10.2217/pgs.15.56 · Cited by 56
Colle, R., Gressier, F., Verstuyft, C., Deflesselle, E., Lépine, J.-P., Ferreri, F., Hardy, P., Guilloux, J.-P., Petit, A.-C., Fève, B., et al. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.01.013 · Cited by 55
“…Asian (Ji et al., 2013; Kang et al., 2010; Katsuki et al., 2012; Tsai et al., 2003) and in Caucasian (Brunoni et al., 2013; Domschke et al., 2010; Kocabas et al., 2011; Licinio et al., 2009; Musil et al., 2013; Taylor et al., 2011; Wilkie et al., 2007) patients, especially two 6-month studies…”
BackgroundMurphy, G. M., Sarginson, J. E., Ryan, H. S., O’Hara, R., Schatzberg, A. F., & Lazzeroni, L. C. (2013) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e328360b175 · Cited by 50
Levran, O., Peles, E., Randesi, M., Shu, X., Ott, J., Shen, P., Adelson, M., & Kreek, M. J. (2013) · Pharmacogenomics · doi:10.2217/pgs.13.58 · Cited by 55
Su, N., Zhang, L., Fei, F., Hu, H., Wang, K., Hui, H., Jiang, X., Li, X., Zhen, H., Li, J., et al. (2011) · Brain Research · doi:10.1016/j.brainres.2011.08.005 · Cited by 51
Yan, T., Wang, L., Kuang, W., Xu, J., Li, S., Chen, J., & Yang, Y. (2014) · Asia-Pacific Psychiatry · doi:10.1111/appy.12148 · Cited by 46
“Indeed, the BDNF gene itself is heterogeneous, encompassing multiple repeat variants (Licinio et al., 2009; Kocabas et al., 2011), and each of them might have an impact on antidepressant efficacy.”
BackgroundFabbri, C., Marsano, A., Albani, D., Chierchia, A., Calati, R., Drago, A., Crisafulli, C., Calabrò, M., Kasper, S. F., Lanzenberger, R. R., et al. (2014) · The Pharmacogenomics Journal · doi:10.1038/tpj.2014.15 · Cited by 41
Self-citationObjective and Measurable Biomarkers in Chronic Subjective Tinnitus
Kang, D. W., Kim, S. S., Park, D.-C., Kim, S. H., & Yeo, S. G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126619 · Cited by 48
The best-laid plans go oft awry: synaptogenic growth factor signaling in neuropsychiatric disease
Williams, A. J., & Umemori, H. (2014) · Frontiers in Synaptic Neuroscience · doi:10.3389/fnsyn.2014.00004 · Cited by 38
Voegeli, G., Cléry-Melin, M.-L., Ramoz, N., & Gorwood, P. A. P. M. (2017) · Drugs · doi:10.1007/s40265-017-0819-9 · Cited by 44
Signaling Pathways Involved in Antidepressant-Induced Cell Proliferation and Synaptic Plasticity
Pilar-Cuéllar, F., Vidal, R., Díaz, Á., Castro, E., Dos-Anjos, S., Vargas, V. I., Romero, B., & Valdizán, E. M. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113196660736 · Cited by 40
Caldwell, W., McInnis, O. A., McQuaid, R. J., Liu, G., Stead, J. D. H., Anisman, H., & Hayley, S. P. (2013) · PLoS ONE · doi:10.1371/journal.pone.0065547 · Cited by 41
Park, D. I., Dournes, C., Sillaber, I., Ising, M., Asara, J. M., Webhofer, C., Filiou, M. D., Müller, M. B., & Turck, C. W. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.39 · Cited by 35
The BDNF Val66Met polymorphism is associated with escitalopram response in depressed patients
El‐Hage, W., Vourc’h, P., Gaillard, P., Léger, J., Belzung, C., Ibargüen-Vargas, Y., Andres, C. R., & Camus, V. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3694-z · Cited by 33
“This suggestion is consistent with the findings of a European study in a Caucasian population, which reported that the Met allele was associated with better responses to 4 weeks of antidepressant treatment (Kocabas et al. 2011).”
ResultWarburton, A., Miyajima, F., Shazadi, K., Crossley, J., Johnson, M. R., Marson, A. G., Baker, G. A., Quinn, J. P., & Sills, G. J. (2015) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2015.11.013 · Cited by 28
Han, E.-J., Kim, Y., Hwang, J.-A., Kim, S. H., Lee, H., Yoon, H., & Na, K.-S. (2015) · Psychiatry Investigation · doi:10.4306/pi.2015.12.1.112 · Cited by 29
Roetker, N. S., Page, C. D., Yonker, J. A., Chang, V. C., Roan, C., Herd, P., Hauser, T. S., Hauser, R. M., & Atwood, C. (2013) · American Journal of Public Health · doi:10.2105/ajph.2012.301141 · Cited by 29
Örenay-Boyacıoğlu, S., Coskunoglu, A., Deveci, A., Bayam, M., Onur, E., Onan, A., & Çam, F. S. (2017) · Noise and Health · doi:10.4103/nah.nah_74_16 · Cited by 27
“There are several studies conducted about mood disorders and responses to antidepressant treatments in MDD patients in reference to the BDNF rs1491850 polymorphism.([32,33]) The BDNF rs2030324 polymorphism was also examined in terms of its relationship with the tendencies toward schizophrenia, asthma, and nicotine add…”
BackgroundNarasimhan, S., Aquino, T. D., Hodge, R., Rickels, K., & Lohoff, F. W. (2011) · Neuroscience Letters · doi:10.1016/j.neulet.2011.08.035 · Cited by 23
Matsumoto, Y., Fabbri, C., Pellegrini, S., Porcelli, S., Politi, P., Bellino, S., Iofrida, C., Mariotti, V., Melissari, E., Menchetti, M., et al. (2014) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-014-0110-7 · Cited by 25
Musil, R., Zill, P., Seemüller, F., Bondy, B., Obermeier, M., Spellmann, I., Bender, W., Adli, M., Heuser, I., Zeiler, J., et al. (2012) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-012-0364-1 · Cited by 27
“Another study found some associations with the A (val) allele and non-response in MDD patients, which would be in accordance [19].”
ResultTeixeira, A. M., Ferreira, J. P., Hogervorst, E., Figueiredo‐Braga, M., Bandelow, S., Rama, L. M. P. L., Figueiredo, A. J., Campos, M. J., Furtado, G. E., Chupel, M. U., et al. (2016) · Frontiers in Public Health · doi:10.3389/fpubh.2016.00133 · Cited by 29
Hennings, J. M., Kohli, M. A., Czamara, D., Giese, M., Eckert, A., Wolf, C., Heck, A., Domschke, K., Arolt, V., Baune, B. T., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064947 · Cited by 26
Wang, X.-C., Xu, D.-J., Chen, G., Xia, Q., & Liu, L. (2014) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000062 · Cited by 22
Avdoshina, V., Mocchetti, I., Liu, C., Young, M., Anastos, K., Cohen, M. H., Crystal, H., Pearce, C. L., Golub, E. T., & Tractenberg, R. E. (2013) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3182a468e9 · Cited by 23
Xu, G., Lin, K., Rao, D., Dang, Y., Ouyang, H., Mai, G., & Zhang, M. (2011) · Psychiatric Genetics · doi:10.1097/ypg.0b013e32834c0c87 · Cited by 18
“…with a recent study in a Caucasian population that reported that the Met allele was associated with better treatment response after 4 weeks of antidepressant treatment (a naturalistic setting with 40% patients receiving of SSRIs) but was not associated with remission (Kocabas et al., 2011).”
BackgroundResultde Assis, G. G., & Hoffman, J. R. (2022) · Brain Plasticity · doi:10.3233/bpl-210132 · Cited by 19
Yang, J., Li, S., Lv, H., Wang, W., Zhang, J., Chu, L., & Zhang, Y. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.09.076 · Cited by 16
Coskun, S., Varol, S., Özdemir, H. H., Ağaçayak, E., Aydin, B., Kapan, O., Camkurt, M. A., TUNÇ, Ş., & Çevik, M. U. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s108814 · Cited by 16
Single nucleotide polymorphisms in the BDNF gene and suicide in the Slovenian sample
Ropret, S., Zupanc, T., Komel, R., & Paska, A. V. (2015) · Neuroscience Letters · doi:10.1016/j.neulet.2015.06.027 · Cited by 16
BDNF gene polymorphisms predicting treatment response to CBT-based rehabilitation of depression
Schosser, A., Fischer-Hansal, D., Swoboda, M. M. M., Ludwig, B., Carlberg, L., Swoboda, P., Kienesberger, K., Bernegger, A., Fuxjäger, M., Zotter, M., et al. (2022) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2022.03.005 · Cited by 17
Self-citationGassó, P., Arnáiz, J. A., Mas, S., Lafuente, A., Bioque, M., Cuesta, M. J., Díaz‐Caneja, C. M., García‐Rizo, C., Lobo, A., González-Pinto, A. M., et al. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881120903462 · Cited by 14
“Although it has been much less frequently studied, this SNP could be functional given its reported association with different brain-related phenotypes (Honea et al., 2013; Park et al., 2013) and treatment response in various psychiatric disorders (Kocabas et al., 2011; Real et al., 2009).”
BackgroundBommaraju, S., Dhokne, M. D., Arun, E. V., Srinivasan, K., Sharma, S. S., & Datusalia, A. K. (2024) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2024.110943 · Cited by 12
BDNF-related mutations in major depressive disorder: a systematic review
Hartig, J., & Nemeş, B. (2022) · Acta Neuropsychiatrica · doi:10.1017/neu.2022.22 · Cited by 15
Kitazawa, M., Ohnuma, T., Takebayashi, Y., Shibata, N., Baba, H., Ohi, K., Yasuda, Y., Nakamura, Y., Aleksić, B., Yoshimi, A., et al. (2012) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32049 · Cited by 12
“, 2012] and depressive symptoms in mood disorders [Tsai et al., 2010; Kocabas et al., 2011].”
BackgroundPharmacogenomics in Psychiatric Practice.
El-Mallakh, R., Roberts, R. J., El-Mallakh, P., Findlay, L. J., & Reynolds, K. K. (2016) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2016.05.001 · Cited by 14
Weber, S., Álvarez, L. T. R., Ansede‐Bermejo, J. J., Cruz, R., del Real, Á., Bühler, J., Carracedo, Á., & Aybek, S. (2024) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2024.111909 · Cited by 11
Serretti, A., Souery, D., Antypa, N., Calati, R., Sentissi, O., Amital, D., Moser, U., Kasper, S. F., Zohar, J., & Mendlewicz, J. (2013) · Psychopathology · doi:10.1159/000345358 · Cited by 11
Self-citationIdentification of a sex-stratified genetic algorithm for opioid addiction risk
Bright, D. R., Langerveld, A. J., DeVuyst-Miller, S., Saadeh, C. E., Choker, A., Lehigh‐Shirey, E., Wheeler, S., Zayzafoon, A., & Sohn, M. (2021) · The Pharmacogenomics Journal · doi:10.1038/s41397-021-00212-0 · Cited by 12
Park, Y.-M., Lee, S., Lee, H., Kang, S., Min, J., & Chae, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060340 · Cited by 11
Schosser, A., Carlberg, L., Calati, R., Serretti, A., Massat, I., Spindelegger, C., Linotte, S., Mendlewicz, J., Souery, D., Zohar, J., et al. (2017) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx028 · Cited by 12
“Association analyses of between BDNF SNPs with and treatment response in MDD were previously published (Kocabas et al., 2011).”
MethodSelf-citationGrant, C. W., Delaney, K., Jackson, L. E., Bobo, J., Hassett, L. C., Wang, L., Weinshilboum, R. M., Croarkin, P. E., Gentry, M. T., Moyer, A. M., et al. (2025) · Clinical and Translational Science · doi:10.1111/cts.70255 · Cited by 15
“Of the 10 publications studying BDNF rs6265 (Val66Met) in patient cohorts comprising multiple antidepressant drugs, three [78–80] found a significant pharmacogenetic association with efficacy outcomes.”
Do we need pharmacogenetics to personalize antidepressant therapy?
Lanni, C., Racchi, M., & Govoni, S. M. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1237-5 · Cited by 9
Singh, P., Srivastava, A., Guin, D., Thakran, S., Yadav, J., Chandna, P., Sood, M., Chadda, R. K., & Kukreti, R. (2023) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyad001 · Cited by 10
Schneider, B., & Prvulovic, D. (2014) · Springer eBooks · doi:10.1007/978-94-007-7740-8_1-1 · Cited by 6
Models for depression recognition and efficacy assessment based on clinical and sequencing data
Hu, Y., Jiang, C., Li, J., & Xu, Z. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e33973 · Cited by 6
“Previous studies have found that BDNF Val66Met SNP, as well as other two BDNF SNPs, were linked to a reduced response to antidepressant treatment suggesting that these SNPs may impact treatment responses to antidepressants [60,61].”
ResultFarzana, F., Vemula, S., Mohiuddin, M. K., Mohan, V., Balakrishna, N., & Ahuja, Y. R. (2015) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4257 · Cited by 4
“…codon 66) was performed using restriction fragment length polymorphisms–polymerase chain reaction (Figure 1(a)) to assess the efficacy of iCST in Met carriers, who have been previously reported to show drug resistance and higher susceptibility to levodopa-induced dyskinesia (Kocabas et al., 2011).”
MethodCortisol and BDNF levels in depression within schizophrenia structure: approach to treating
Nikiforova, Y. S., & Mazo, G. E. (2016) · Reviews on Clinical Pharmacology and Drug Therapy · doi:10.17816/rcf14312-17 · Cited by 4
Treatment-Resistant Depression: An Overview
Moukaddam, N. J., & Shah, A. A. (2016) · Psychiatric Annals · doi:10.3928/00485713-20160215-01 · Cited by 4
Pharmacogenetics in Electroconvulsive Therapy and Adjunctive Medications
Mirzakhani, H., van Noorden, M. S., Swen, J. J., Nozari, A., & Guchelaar, H. (2015) · Pharmacogenomics · doi:10.2217/pgs.15.57 · Cited by 4
Sun, Q., Yuan, F., Ren, D., Ma, G., Yang, F., Wu, X., He, L., & He, G. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s191376 · Cited by 2
Genetics of Treatment‐resistant Depression
Fabbri, C., Porcelli, S., & Serretti, A. (2013) · Wiley eBooks · doi:10.1002/9781118556719.ch3 · Cited by 2
Pharmacogenetics of antidepressant drugs: An update
Crisafulli, C., Drago, A., Calabrò, M., Sidoti, A., Serretti, A., & Spina, E. (2014) · Hospital Pharmacology - International Multidisciplinary Journal · doi:10.5937/hpimj1401033c · Cited by 2
“Pharmacogenetic studies mainly suggested a positive molecular heterosis effect [171, 172, 173], together with a more favorable outcome in Met allele carriers [174-177].”
BackgroundSchneider, B., & Prvulovic, D. (2015) · Biomarkers in disease · doi:10.1007/978-94-007-7696-8_1 · Cited by 1
The Neuroprotective Potential of STN DBS and the Role of BDNF
Fischer, D. L. (2015) · Michigan State University Libraries · doi:10.25335/m5s778
Metadata
- Authors
- Kocabas, N. A., Antonijevic, I., Faghel, C., Forray, C., Kasper, S., Lecrubier, Y., Linotte, S., Massat, I., Mendlewicz, J., Noro, M., Montgomery, S., Oswald, P., Snyder, L., Zohar, J., & Souery, D.
- Affiliations
- Lundbeck (United States) (US)
- Medical University of Vienna (AT)
- Inserm (FR)
- Fund for Scientific Research (BE)
- Université Libre de Bruxelles (BE)
- Imperial College London (GB)
- Sheba Medical Center (IL)
- ORCID
- Venue
- International Clinical Psychopharmacology
- Published
- 2011-01
- Volume
- 26
- Issue
- 1
- Pages
- 1-10
- ISSN
- 0268-1315 (ISSN-L)
- OpenAlex
- W2079527591
- Cited by
- 74
- References
- 46
- Citations by year
- 2025: 1 · 2024: 3 · 2023: 2 · 2022: 4 · 2021: 4 · 2020: 2 · 2019: 3 · 2017: 4 · 2016: 5 · 2015: 12 · 2014: 12 · 2013: 13 · 2012: 6
- FWCI
- 3.95
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- International Clinical Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- Funders
- Fonds De La Recherche Scientifique - FNRS
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- brain-derived neurotrophic factor, BDNF gene polymorphism, major depressive disorder, antidepressant response, antidepressant non-response, BDNF Val66Met polymorphism, tagging SNPs, haplotypes, genetic susceptibility to depression, neurotrophins
- MeSH terms
- Alleles, Antidepressive Agents, Major Depressive Disorder, Female, Gene Frequency, Genotype, Haplotypes, Humans, Male, Middle Aged, Phenotype, Remission Induction, Treatment Outcome, Brain-Derived Neurotrophic Factor, Polymorphism, Single Nucleotide
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.